RxDoctor Payments Data

Amanda Ellenburg, PA

Physician Assistant · Boerne, TXNPI 1013442664

Payments from drug & device makers

$6,459in general payments, 2019–2025

Across 217 payments — averaging $29.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$799
  • Boehringer Ingelheim$721
  • Bayer$507
  • Lilly USA, LLC$493
  • GSK$388
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,39699%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,459 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$55,744
Medicare patients
298
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$54,901
FarxigaDapagliflozin Propanediol18$19,858
JardianceEmpagliflozin12$18,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,774
Olmesartan Medoxomil27$1,229
Nifedipine ErNifedipine39$1,138
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide43$1,123
Levocetirizine Dihydrochloride77$1,091
Fluticasone Propionate78$918
Atorvastatin Calcium100$778
Rosuvastatin Calcium53$717
Albuterol Sulfate HfaAlbuterol Sulfate33$625
Metoprolol Succinate56$561
Omeprazole42$550
Diclofenac Sodium15$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$799$54,90142 claims
AstraZenecaFarxiga$1,537$19,85818 claims
Boehringer IngelheimJardiance$721$18,88012 claims
GSKTrelegy Ellipta$388$12,77414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →